ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--

ImmunoGen, Inc. IMGN, a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference. ImmunoGen President and CEO Daniel Junius will discuss the Company in a "fireside chat" moderated question and answer session that will be webcast beginning at 2:50 pm ET on September 16, 2015.

This webcast will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla^® is the first marketed product with ImmunoGen's ADC technology. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150910006252/en/